In-silico prediction of HLA-DP and -DQ epitope content is poorly correlated with clinical immunogenicity of therapeutic proteins by Admin Epivax | Oct 21, 2016
T-Cell Dependent Immunogenicity of Protein Therapeutics: Preclinical Assessment and Mitigation by Admin Epivax | Oct 21, 2016
Tolerization as a Rational Design Approach for Reducing the Immunogenicity of Biologics (Campath) by Admin Epivax | Oct 21, 2016
Regulating Immune Responses to Biologics: Validation of Screening, Deimmunization and Tolerization Approaches by Admin Epivax | Oct 21, 2016